Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid

Published:2022-12-13 Issue:5 Volume:50 Page:705-709
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Kwon Il Joo¹^ORCID,Kim Taehee¹^ORCID,Yoo Dae San¹^ORCID,Min Seoyeon¹^ORCID,Kim Soo‐Chan²^ORCID,Kim Jong Hoon¹^ORCID

Affiliation:

1. Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute Yonsei University College of Medicine Seoul Korea

2. Department of Dermatology, Yongin Severance Hospital, Cutaneous Biology Research Institute Yonsei University College of Medicine Seoul Korea

Funder

Yonsei University College of Medicine

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.16678

Reference12 articles.

1. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature

2. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity

3. A Pathogenic Role for IgE in Autoimmunity: Bullous Pemphigoid IgE Reproduces the Early Phase of Lesion Development in Human Skin Grafted to nu/nu Mice

4. Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid

5. Mortality of patients with bullous pemphigoid in Korea

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review;Journal of Clinical Medicine;2024-08-16

2. Rituximab;Reactions Weekly;2024-07-20

3. Spontanremission der Urtikaria: Gibt es das, und wenn ja, wann?;Die Dermatologie;2024-03-11

4. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid;JAMA Dermatology;2024-01-01

5. Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases;Allergy;2023-08-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3